RxDoctor Payments Data

Allyson Hale

Physician Assistant · Greenville, SCNPI 1437861713

Payments from drug & device makers

$573in general payments, 2019–2025

Across 28 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$257
  • Abbott$126
  • Corcept Therapeutics$64
  • Amgen$34
  • Organon$32
  • AstraZeneca$24
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk16$257
Abbott1$126
Corcept Therapeutics4$64
Amgen2$34
Organon2$32
AstraZeneca1$24
Pfizer1$22
Lilly USA, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$573 in reported general payments places this provider in the 55th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$208
Medicare patients
15
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$46,462
JardianceEmpagliflozin47$42,399
JanuviaSitagliptin Phosphate43$40,394
MounjaroTirzepatide23$25,829
FarxigaDapagliflozin Propanediol38$20,277
XareltoRivaroxaban21$15,030
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,519
SymbicortBudesonide/Formoterol Fumarate31$6,711
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,486
Albuterol Sulfate HfaAlbuterol Sulfate106$3,146
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,548
Atorvastatin Calcium206$1,617
Famotidine108$1,272
Trazodone Hcl51$1,142
Lisinopril145$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$257$46,46242 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$24$36,50885 claims
Lilly USA, LLCMounjaro$14$25,82923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →